Table 1 Cytotoxic effect and pharmacological interaction of gemcitabine and pemetrexed against bladder cancer cell lines

From: In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients

 

IC50 values (n M)a

 

T24

J82

Times (h)

Gemcitabine

Pemetrexed

Gemcitabine

Pemetrexed

 1

91.7±5.1

6392.9±958.9

4366.7±833.3

38194.0±7638.8

 6

35.2±2.9

156.6±26.6

166.7±33.3

25642.2±5384.8

24

6.1±0.4

64.9±5.3

5.7±1.0

2566.9±339.4

48

2.1±0.4

22.5±2.8

5.2±0.8

63.6±4.2

 

CI values b

Fa

Gemcitabine-Pemetrexed

Pemetrexed-Gemcitabine

Gemcitabine-Pemetrexed

Pemetrexed-Gemcitabine

0.50

0.80

0.17

0.04

0.05

0.75

0.25

0.09

0.03

0.05

0.90

0.09

0.05

0.05

0.09

  1. aIC50s were calculated as mean values±s.d. of at least three MTT independent experiments after 2, 6, 24 and 48 h of continuous exposure.
  2. bCombination Index (CI) values were calculated as mean values from three separate experiments, at fraction affected (FA) of 0.50, 0.75 and 0.90 in cells exposed to gemcitabine and pemetrexed combinations, as explained in the Materials and methods section.
Back to article page